Kai-Ping Zhang, Xian-Guo Chen, Li Zhang, Cheng Yang, Chao-Zhao Liang
Department of Urology, The First Affiliated Hospital of Anhui Medical University and Institute of Urology, Anhui Medical University, Hefei, Anhui, China (mainland)
Med Sci Rev 2015; 2:121-129
The association between IL-10 polymorphisms (–1082G>A, –819T>C, –592A>C, and 210T>C) and urologic neoplasms risk, including prostate cancer (PCa), bladder cancer (BCa), and renal cell cancer (RCC), have remained controversial. Hence, we conducted a meta-analysis to search for comprehensive associations between IL-10 polymorphisms and urologic neoplasms risk.
MATERIAL AND METHODS: All relevant studies were searched from databases using STATA12.0 statistical software. In addition, ORs of fixed- or random-effects models and 95%CI were calculated.
RESULTS: Eighteen published studies consisting of 7679 cases and 8491 controls were included. No significant association were identified between any of IL-10 polymorphisms and urologic neoplasms (–1082G>A, G vs. A: OR=0.92, 95%CI 0.83–1.02; GG vs. AA: OR=0.86, 95%CI 0.69–1.06; GA vs. AA: OR=0.92,95%CI 0.80–1.05; GG vs. GA+AA: OR=0.92, 95%CI 0.77–1.11; GG + GA vs. AA: OR=0.89, 95%CI 0.78–1.03). In the stratified analyses by ethnicity, cancer types, control sources, genotyped methods, and sample sizes, no evidence was found to support this association. The results were similar among the IL-10-819T>C, –592A>C, and 210T>C polymorphisms and cancer risk, regardless of whole group or subgroups.
CONCLUSIONS: This meta-analysis revealed that IL-10–1082G>A, –819T>C, –592A>C, and 210T>C polymorphisms are not related to urologic neoplasms risk. Well-designed studies are needed to confirm our findings.
Keywords: Genetic Association Studies, Interleukin-10, Polymorphism, Genetic, Urologic Neoplasms